Smoking cessation medicines does not raise serious cardiovascular event risk

A study published in JAMA Internal Medicine examined whether smoking cessation treatments increases the risk of serious cardiovascular events.

Researchers conducted a double-blind, randomized trial and a nontreatment extension trial at 140 multinational centers. They studied 8,058 smokers who received at least 1 dose of study medication as well as a subset of 4,595 who completed 12 weeks of treatment and 12 weeks of follow up and agreed to be followed up for an additional 28 weeks.

The smoking cessation treatments included Varenicline, bupropion hydrochloride and nicotine replacement therapy.

The study shows a low incidence of cardiovascular events during treatment and follow-up and the risk of cardiovascular events did not differ significantly by treatment. Additionally, no significant treatment differences were observed in time to cardiovascular events, blood pressure or heart rate.

More articles on healthcare quality: 
Study: Early HIV infection treatment could help stop brain damage
UTHealth: 3 priorities for outpatient infection prevention
How hospitals can strengthen peel pouch sealing processes

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars